Combinatorial and/or sequential inhibition of CD133 signaling to PI3K/AKT/mTOR and PI3K/RAS/RAF/MEK/ERK pathways, after first-line immunotherapy, may extend the anti-tumor response for melanoma patients. Here, MTOR is linked to neoplasm.